Intradialytic Kinetics of Cardiac Biomarkers During Hemodialysis and Hemodiafiltration
NCT ID: NCT06526702
Last Updated: 2025-10-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
26 participants
INTERVENTIONAL
2024-09-12
2025-04-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In 24 patients treated with maintenance hemodialysis, the study will compare high-flux hemodialysis (HD) with post-dilution hemodiafiltration (HDF) to investigate:
* Baseline concentrations and week-to-week plasma variations of the cardiac biomarkers.
* Changes in the plasma concentrations of the cardiac biomarkers during high-flux HD and post-dilution HDF.
* Dialyzer clearance of the cardiac biomarkers in high-flux HD and post-dilution HDF.
* Adherence of the cardiac biomarkers to the dialyzer membrane.
* Concentrations of the cardiac biomarkers 30 minutes post-dialysis to investigate a potential rebound effect.
Additionally, a sub-study of 24 patients treated with peritoneal dialysis will investigate the baseline concentrations and week-to-week plasma variations of the same cardiac biomarkers.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers of Cardiovascular Complications in Chronic Kidney Disease
NCT03274921
Kidney Disease Biomarkers
NCT00255398
The Impact of Selected Factors on the Cardiovascular System in Chronic Kidney Disease
NCT05214872
Assessment of D-dimer and CRP for Cardiovascular Risk Prediction in Hemodialysis Patients
NCT07130721
Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients
NCT02207153
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Single-center, randomized, crossover study with 24 participants. The study will investigate the effect of high-flux HD (using the FX CorDiax 100 dialyzer) and post-dilution HDF (using the FX CorDiax 1000 dialyzer) on the intradialytic kinetics of selected cardiac biomarkers. The study will not be blinded, but the order of the interventions will be randomized. The two dialysis sessions will be conducted on the same weekday. Between the two interventions, the patient will have a wash-out period of 1-3 weeks with standard dialysis treatment.
On both trial days, the following dialysis settings will be the same for each individual patient:
* The dialysis sessions will last 4 hours.
* The same dialysis machine will be used, either the Fresenius Medical Care 5008 or 6008 CAREsystem machine.
* Same vascular access will be used.
* The composition of electrolytes in the dialysate will be the same.
* Blood flow rate will be \>300 mL per minute and consistent.
* Dialysate flow rate will be 500 mL per minute.
* Ultrafiltration rate will be constant aiming at dry weight.
* Routine anticoagulation protocol will be unchanged, but consistent on both trial days.
* Routine dialysate temperature will be unchanged, but consistent on both trial days.
On both trial days, different baseline characteristics will be gathered, including demographic data, clinical data, dialysis characteristics, and routine blood samples. Blood samples, for the analysis of the selected cardiac biomarkers, will be collected:
* Before the dialysis session is started (baseline).
* After 10, 30, 60, 120, 180, and 240 minutes of dialysis. All samples will be collected from the blood dialyzer inlet; however, halfway into the dialysis session (after 120 minutes), samples will also be collected from the blood dialyzer outlet and from the dialysate.
* 30 minutes after dialysis cessation. However, if the patient will not stay 30 minutes, the post-dialysis sample will be gathered after 5 minutes.
Sub-study of patients treated with peritoneal dialysis:
In a sub-study, 24 patients treated with peritoneal dialysis, will be included for one or two venous blood samples (with a minimum of 1 week between) to determine the baseline concentration and week-to-week variation of the cardiac biomarkers of interest. On both trial days, different baseline characteristics will be gathered, including demographic data, clinical data, dialysis characteristics, and routine blood samples.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High-flux hemodialysis then post-dilution hemodiafiltration
Participants will first receive high-flux hemodialysis. Following a washout period of 1-3 weeks, they will receive post-dilution hemodiafiltration.
High-flux hemodialysis
FX CorDiax 100 dialyzer
Post-dilution hemodiafiltration
FX CorDiax 1000 dialyzer
Post-dilution hemodiafiltration then high-flux hemodialysis
Participants will first receive post-dilution hemodiafiltration. Following a washout period of 1-3 weeks, they will receive high-flux hemodialysis.
High-flux hemodialysis
FX CorDiax 100 dialyzer
Post-dilution hemodiafiltration
FX CorDiax 1000 dialyzer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High-flux hemodialysis
FX CorDiax 100 dialyzer
Post-dilution hemodiafiltration
FX CorDiax 1000 dialyzer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinically stable patients with end-stage renal disease treated with maintenance hemodialysis or peritoneal dialysis.
* Regarding patients treated with hemodialysis: Dialysis access with an arteriovenous fistula and able to maintain a blood flow rate \>300 mL.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aalborg University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Caroline Hundborg Liboriussen
Principal Investigator, Medical Doctor, and PhD student at the Department of Nephrology, Aalborg University Hospital, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Nephrology, Aalborg University Hospital
Aalborg, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
F2024-045 and N-20240016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.